SLC Transporter Knockout Cells: From Metabolic Regulation to Drug Target Discovery

SLC Transporter Knockout Cells: From Metabolic Regulation to Drug Target Discovery

The Solute Carrier (SLC) superfamily is the largest group of transmembrane transporter proteins in the human body, with its encoding genes accounting for approximately 5.2% of the human protein-coding genome. From glucose and amino acids to drug molecules, SLCs regulate the transmembrane transport of virtually all essential substances for life.

In recent years, driven by advances in functional genomics and high-throughput screening technologies, SLC transporters have transitioned from being "underappreciated supporting roles" to core targets in the fields of metabolic diseases, oncology, and drug development. Gene knockout (KO) cell models have thus emerged as the gold-standard tools for elucidating SLC functions and validating these drug targets.

Why is the SLC Superfamily an Emerging Target of Interest?

The SLC superfamily comprises approximately 460 members distributed across 76 families, along with 52 SLC-like proteins, bringing the total to 516. They act not only as the gatekeepers for nutrients entering and exiting the cell, but their dysfunction is also directly implicated in the pathogenesis of various major diseases.

l Tumor Metabolism: SLC members such as GLUT1, LAT1, ASCT2, and xCT drive tumor metabolic reprogramming. Selective inhibitors targeting these transporters have already entered preclinical studies.
l Cardiovascular and Metabolic Diseases: The SLC2A family is associated with diabetes; the SLC22A family (OATs, OCTs) is involved in the transport of drugs and metabolites, impacting blood pressure and lipid levels.
l Neurodegenerative Diseases: SLC1A2 (GLT-1) dysfunction is linked to amyotrophic lateral sclerosis (ALS); SLC6A4 (SERT) is associated with depression.
l Drug ADME (Absorption, Distribution, Metabolism, and Excretion): Transporters like OAT1 (SLC22A6) and OCT2 (SLC22A2) determine the renal clearance rate of drugs, profoundly affecting drug efficacy and toxicity.

Why are SLC Gene-Edited Cells Powerful Tools for Functional Research?

CRISPR/Cas9-mediated gene knockout achieves complete loss of target gene function at the genomic level, offering irreplaceable advantages:

l Complete Loss of Function: Knockout leads to total protein inactivation, yielding clear phenotypes and high reproducibility.
l Stable Inheritance: Monoclonal cell lines can be passaged long-term without the need for repeated transfections.
l Suitability for High-Throughput Screening: They can be utilized to construct SLC family knockout libraries for systematic genetic interaction profiling.

A 2025 study published in Molecular Systems Biology mapped the large-scale genetic interactions of the human SLC superfamily using the CRISPR system. By screening 35,421 pairs of SLC-SLC double knockouts, researchers discovered that cellular transport systems exhibit remarkable metabolic redundancy and robustness, with only 0.67% of SLC-SLC gene pairs displaying genetic interactions.

This finding suggests that targeting a single SLC may be insufficient to produce a distinct phenotype, necessitating combinatorial knockouts or functional synergy analyses.

Beyond knockout strategies, point mutation models are another crucial tool for deciphering SLC functions. Many disease-associated SLC mutations are missense mutations (single amino acid substitutions) rather than a complete loss of function. Through CRISPR-mediated precise point mutations, researchers can:

l Model specific SLC missense mutations found in human genetic diseases.
l Investigate the impact of critical amino acid residues on transport activity and substrate selectivity.
l Screen for specific inhibitors targeting mutant variants.

Representative Applications of SLC Knockout Cells in Translational Research

1. SLC38A1: A Novel Metabolic Therapeutic Target in MDS/AML
SLC38A1 is a non-classical glutamine transporter.

A study presented at the 2025 AACR Annual Meeting revealed that SLC38A1 is significantly overexpressed in the long-term hematopoietic stem cells of patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), which correlates with shortened overall survival.

Utilizing CRISPR-mediated SLC38A1 knockout, researchers demonstrated a 37%, 42%, and 43% reduction in surviving colonies in MOLM13, THP-1, and MDS-L cells, respectively. Similarly, knockout effectively suppressed cell viability and colony-forming capacity in primary samples from AML and high-risk MDS patients.

This study indicates that metabolic intervention strategies targeting SLC38A1 hold promise for providing new therapeutic options for MDS/AML patients.

2. SLC22A6 (OAT1): A Classic Model for Renal Drug Transport
Organic anion transporter 1 (OAT1/SLC22A6) is expressed in renal proximal tubule cells, mediating the uptake of numerous clinical drugs, including antivirals, antibiotics, and diuretics. Loss of OAT1 function can lead to decreased drug clearance, heightening the risk of toxicity.

By leveraging SLC22A6 knockout cell models, researchers can evaluate whether candidate compounds are OAT1 substrates, predict drug-drug interactions, and screen for new molecular entities with low nephrotoxicity.

3. SLC35A1: Viral Receptor and Gene Therapy Tool

SLC35A1 encodes a CMP-sialic acid transporter responsible for the sialylation of cell surface glycoproteins, acting as a critical receptor for the entry of various viruses, such as influenza and parainfluenza, into host cells.

Genome-wide CRISPR screening has confirmed that SLC35A1 knockout significantly inhibits viral replication.

Furthermore, knocking out SLC35A1 in HEK293T and HeLa cells enhances the transduction efficiency of AAV9, providing an optimized tool for testing gene therapy efficacy.

How to Efficiently Conduct SLC Functional Research?
Off-the-Shelf SLC KO/Point Mutation Cell Libraries

Facing hundreds of members in the SLC family, generating knockout cells one by one is both time-consuming and costly. EDITGENE offers off-the-shelf SLC gene-edited cells covering a wide range of highly researched transporter targets, empowering you to focus your energy on core scientific questions.

Product Advantages:
l Constructed using CRISPR/Cas9 technology, ensuring monoclonal purity with knockout verified by Sanger sequencing.
l Off-the-shelf availability for immediate shipping, saving 2-3 months of cell line construction time.
l Multiple cell backgrounds available: HEK293, HeLa, Huh-7, HCT116, etc.
l Validation data included: Sequencing chromatograms are provided.

Partial List of Off-the-Shelf SLC Knockout Cells

For more SLC family knockout cells (e.g., sodium, potassium, and calcium ion channels) and custom services, please contact EDITGENE customer support.

Conclusion

The SLC transporter family is stepping out of the "supporting" shadows in basic research to become the "leading star" in drug target discovery. Whether exploring tumor metabolic reprogramming, deciphering drug transport mechanisms, or developing novel therapeutic strategies, SLC knockout cell models remain an indispensable core tool.

EDITGENE’s off-the-shelf SLC knockout cell library accelerates every step of your research through professional technology, reliable validation, and rapid delivery.

References

1. Gyimesi, G., et al. (2025). The SLC-ome of membrane transport: From molecular discovery to physiology and clinical applications. Physiological Reviews. Advance online publication.
2. Alam, S., et al. (2023). Membrane transporters in cell physiology, cancer metabolism and drug response. Disease Models & Mechanisms, 16(11), dmm050404.
3. Gou, X., et al. (2022). Construction and evaluation of a novel organic anion transporter 1/3 CRISPR/Cas9 double-knockout rat model. Pharmaceutics, 14(11), 2307.
4. Girardi, E., et al. (2020). A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nature Chemical Biology, 16(4), 469–478.